BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 16, 2015
 |  BioCentury  |  Emerging Company Profile

Bridge to POC

How BRIM is bridging a translational science gap in Taiwan

BRIM Biotechnology Inc. has assembled a team of translational science veterans to fill what it sees as a gap in Taiwanese drug development capabilities. The company plans to bring in preclinical projects with global commercialization potential and develop them through Phase Ia or IIb proof of concept, then sell them or find a partner to complete development outside of Taiwan or Asia.

BRIM seeks global rights to programs from academic groups, multinationals and biotechs. The company has four preclinical programs, including two cancer biologics and one dengue fever collaboration with a Johnson & Johnson unit.

"By the time we reach proof of concept in clinical studies, that's where we pursue an exit strategy by out-licensing or collaborating with other companies," said CEO Haishan Jang.

Jang was senior director at J&J's Centocor Research and Development Inc. unit and spent the past five years working at private Taiwanese companies and research institutions affiliated with the Taiwanese government.

She said Taiwanese researchers often find translational science challenging because...

Read the full 834 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >